Nasopharyngeal carcinoma in children and adolescents - a single institution experience of 158 patients

Radiation Oncology

Table 2 Univariate analysis (log-rank test)

Factors	5-y OS %	Pvalue	5-y LRC %	Pvalue	5-y DMFS %	Pvalue
Gender		0.43		0.48		0.07
Male	81.1		93.9		73.0
Female	86.6		97.4		86.6
Age		0.17		0.54		0.76
≤16	78.4		95.6		77.2
>16	87.5		94.0		75.5
History		0.45		0.98		0.92
≤6 m	80.5		94.7		77.1
>6 m	87.7		95.2		74.7
UICC-T
		0.80		0.67		0.99
T1	66.7		100		75.0
T2-4	82.9		94.7		76.5
		0.34		0.77		0.64
T1-2	83.3		93.1		78.7
T3-4	82.3		95.4		75.7
		0.01		0.32		0.54
T1-3	87.9		96.2		76.9
T4	75.0		92.9		75.7
UICC-N
		0.95		0.48		0.30
N0	77.1		100		90.0
N1-3	82.9		94.5		75.4
		0.48		0.10		0.19
N0-1	89.6		100		83.3
N2-3	79.9		92.8		73.8
		0.51		0.61		0.45
N0-2	83.8		95.6		75.2
N3	77.8		92.6		81.2
UICC stage
		0.57		0.53		0.36
II	85.7		100		88.9
III-IV	82.4		94.6		75.7
		0.04		0.10		0.87
II-III	90.0		98.4		75.9
IV	77.1		92.0		76.9
Treatment		0.54		0.36		0.57
Radiotherapy alone	82.9		93.0		77.8
Modality therapy	82.7		97.2		75.0
Neoadjuvant chemotherapy		0.70		0.25		0.85
Yes	87.3		100		78.6
No	80.8		93.9		76.1
Concurrent chemotherapy		0.17		0.58		0.71
Yes	85.3		97.6		78.8
No	67.3		100		75.5
Adjuvant chemotherapy		0.30		0.27		0.68
Yes	90.0		89.7		80.0
No	72.9		100		75.9
Technology		0.33		0.74		0.42
2D	79.5		94.2		74.0
IMRT	88.7		96.1		81.1
Dose		0.45		0.45		0.63
>70 Gy	86.8		93.7		74.2
≤70 Gy	77.1		96.6		79.4
Response		0.11		0.21		0.46
PR	75.2		92.1		74.5
CR	89.2		97.2		79.4

ISSN: 1748-717X